

H2APEX Group SCA
société en commandite par actions
Registered Office: 19, rue de Flaxweiler, L-6776 Grevenmacher,
Grand Duchy of Luxembourg
R.C.S. Luxembourg B148525

**PARTICIPATION FORM, PROXY FORM AND CORRESPONDENCE VOTING FORM FOR THE
ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING OF
SHAREHOLDERS TO BE HELD ON 17 JUNE 2026**

Dear Shareholder,

On 3 June 2026 at 12:00 p.m. (midnight) CEST (the **Record Date**), you are holding (a) share(s) of **H2APEX Group SCA**, a partnership limited by shares (*société en commandite par actions*) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 19, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg, and registered with the Luxembourg Trade and Companies Register (*Registre de Commerce et des Sociétés de Luxembourg*) under number B148525 (the **Company**),

and are therefore entitled to participate at the annual general meeting (the **AGM**) and at the extraordinary general meeting (the **EGM**) of shareholders of the Company which will be held on 17 June 2026 at 11:00 a.m. CEST at Elvinger Hoss Prussen, 5, place Winston Churchill, L-1340 Luxembourg, Grand Duchy of Luxembourg (the AGM and the EGM together referred to as the **Meetings**).

I. Agenda of the AGM

At the AGM, the shareholders of the Company shall deliberate and vote on the following agenda items:

1. Presentation of the report of the independent auditor on the annual accounts of the Company for the financial year ended on 31 December 2025 (the **2025 Financial Year**);
2. Approval of the annual accounts of the Company for the 2025 Financial Year;
3. Acknowledgment of the Company's results made with respect to the 2025 Financial Year, and resolution concerning the allocation of the results;
4. Presentation of the management report issued by the manager and general partner of the Company (the **General Partner**) and the report of the independent auditor on the consolidated accounts for the 2025 Financial Year;
5. Approval of the consolidated accounts for the 2025 Financial Year;
6. Granting of discharge (*quitus*) to Mr. Georges Bock, member of the supervisory board of the Company (the **Supervisory Board**), for the exercise of his mandate during the 2025 Financial Year;
7. Granting of discharge (*quitus*) to Prof. Dr. Heinz Jörg Fuhrmann, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
8. Granting of discharge (*quitus*) to Mr. Roland Lienau, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
9. Granting of discharge (*quitus*) to Mr. Florian Schuhbauer, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
10. Granting of discharge (*quitus*) to Mr. Thomas Terschluse, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
11. Granting of discharge (*quitus*) to Mr. Markus Lesser, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;

12. Granting of discharge (*quitus*) to Mr. Klaus Röhrig, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
13. Granting of discharge (*quitus*) to the General Partner for the exercise of its mandate as manager of the Company for the 2025 Financial Year;
14. Presentation of and advisory vote on the remuneration report for the 2025 Financial Year;
15. Approval of the fixed annual remuneration of the members of the Supervisory Board for the 2026 Financial Year;
16. Renewal of the mandate of Mr. Georges Bock as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
17. Renewal of the mandate of Prof. Dr. Heinz Jörg Fuhrmann as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
18. Renewal of the mandate of Mr. Roland Lienau as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
19. Renewal of the mandate of Mr. Thomas Terschluse as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
20. Renewal of the mandate of Mr. Markus Lesser as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
21. Renewal of the mandate of Mr. Klaus Röhrig as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
22. Decision to renew BDO Audit's mandate as independent auditor (*réviseur d'entreprises agréé*) of the Company for a term expiring at the annual general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2026 to be held in 2027; and
23. Miscellaneous.

II. Agenda of the EGM

At the EGM, the shareholders of the Company shall deliberate and vote on the following agenda items:

1. Acknowledgment of the report prepared by the General Partner of the Company in accordance with Article 420-26(5) of the Luxembourg law dated 10 August 1915 on commercial companies, as amended (the Law) regarding the proposed renewal of the authorised capital of the Company and the authorisation to limit or suppress the preferential subscription rights of existing shareholders regarding shares issued thereunder;
2. Decision to renew the authorised capital of the Company, for a new period of five years starting on the date of the EGM, and to grant the authorisation to the General Partner to issue up to one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) ordinary shares;

3. Decision to authorise the General Partner to limit or suppress the preferential subscription rights of existing shareholders in the event of any increase in the issued share capital up to and including the authorised capital;
4. Decision to amend article 5.4 of the Company's articles of association so as to read as follows:

“5.4 The authorised capital, excluding the issued share capital, is set at two million three hundred forty-one thousand one hundred nine euro and twenty-four cents (EUR 2,341,109.24), consisting of one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) Ordinary Shares without nominal value. During a period of five (5) years from the extraordinary general meeting of shareholders of the Company held on 17 June 2026, the Manager is hereby authorised to issue Ordinary Shares to such persons and on such terms as they shall see fit and specifically to proceed to such issue without reserving a preferential right to subscribe to the shares issued for the existing shareholders, and it being understood, that any issuance of such instruments will reduce the available authorised capital accordingly. The authorised capital of the Company may be increased or reduced by a resolution of the general meeting of shareholders adopted in the manner required for an amendment of these articles of association. The above authorisations may be renewed through a resolution of the general meeting of the shareholders adopted in the manner required for an amendment of these articles of association and subject to the provisions of the Law, each time for a period not exceeding five (5) years.”

5. Decision to include an additional article 5.5 and an additional article 5.6 in the Company's articles of association which shall read as follows:

“5.5 The Manager is authorised to determine the conditions of any capital increase within the limits of the authorised capital including through contributions in cash or in kind, by the incorporation of reserves, issue premiums or retained earnings, with or without the issue of new Ordinary Shares, or following the issue and the exercise of subordinated or non-subordinated bonds, convertible into or repayable by or exchangeable for Ordinary Shares (whether provided in the terms at issue or subsequently provided), or following the issue of bonds with warrants or other rights to subscribe for Ordinary Shares attached, or through the issue of stand-alone warrants or any other instrument carrying an entitlement to, or the right to subscribe for, Ordinary Shares.

5.6 The Manager is authorised to set the subscription price, with or without issue premium, the date from which the Ordinary Shares or other financial instruments will carry beneficial rights and, if applicable, the duration, amortisation, other rights (including early repayment), interest rates, conversion rates and exchange rates of the aforesaid financial instruments as well as all the other conditions and terms of such financial instruments including as to their subscription, issue and payment, for which the Manager may make use of Article 420-23 paragraph 3 of the Law.”

III. Right to participate at the Meetings

To participate and vote at the Meetings, you must observe the following steps:

1. Complete and sign the participation declaration attached hereto as Schedule 1 (the **Participation Declaration**) and return it to the Company's centralizing agent, **CAPTRACE GmbH**, with registered office at Äppelallee 27, 65203 Wiesbaden, Germany, attn: Ms Corinna Fischer (fax: +49 8943780823 and e-mail: agm@captrace.com) (the **Centralizing Agent**) no later than on 14 June 2026 at 11:59 p.m. CEST by mail, fax or e-mail (provided that by sending a Record Date Attestation (as defined

below) in accordance with point 2 below, you shall be deemed to have confirmed your intention to participate at the Meetings and no separate declaration will be required in that respect);

2. Obtain the certificate from your securities settlement system operator or depositary (or sub-depositary) that confirms the number of shares you hold in the Company on the Record Date (the **Record Date Attestation**) and return it by mail, fax or e-mail to the Centralizing Agent no later than on 14 June 2026 at 11:59 p.m. CEST; and
3. Decide how you want to participate: in person, by proxy or by correspondence, as detailed below.

A. In-person attendance

In case you want to attend in person, and subject to compliance with the prior formalities set out under point 1, you may attend the Meetings provided you carry proof of identity.

B. Proxy

In case you do not wish to attend the Meetings in person, you can appoint another person as your representative by completing and signing the proxy in the form attached hereto as Schedule 2 (the **Proxy Form**) and returning it to the Centralizing Agent no later than on 14 June 2026 at 11:59 p.m. CEST by mail, fax or e-mail.

In case you wish to give proxy to a person having a potential conflict of interest, you must give the conflicted proxy holder specific voting instructions in the proxy.

C. Vote by correspondence

In case you wish to vote by correspondence, you must complete and sign the correspondence voting form attached hereto as Schedule 3 (the **Correspondence Voting Form**) and return it to the Centralizing Agent no later than on 14 June 2026 at 11:59 p.m. CEST by mail, fax or by e-mail.

IV. Changing or cancelling your participation

If you send a Proxy Form and a Correspondence Voting Form at the same time, the latter shall prevail.

If you have sent a Correspondence Voting Form but want to change or cancel it, you can do so by sending a later dated Proxy Form or Correspondence Voting Form, or by writing to the Centralizing Agent to cancel it, as long as you do so no later than 14 June 2026 at 11:59 p.m. CEST.

Schedule 1

PARTICIPATION DECLARATION FOR THE ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

The undersigned, _____, having his/her/its registered office/address at _____ and, if applicable, with commercial register number _____ (the **Shareholder**),

in his/her/its capacity as shareholder of the Company (as defined below), holding _____ ordinary shares, as shown on the attached copy/-ies of the certificate(s) evidencing the shareholding on the Record Date of **H2APEX Group SCA**, a partnership limited by shares (*société en commandite par actions*) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 19, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg, and registered with the Luxembourg Trade and Companies Register (*Registre du Commerce et des Sociétés de Luxembourg*) under number B148525 (the **Company**),

hereby declares that he/she/it is participating at the annual general meeting and the extraordinary general meeting of shareholders of the Company to be held on 17 June 2026 at 11:00 a.m. CEST with the following agenda (the **Meetings**):

I. Agenda of the AGM

1. Presentation of the report of the independent auditor on the annual accounts of the Company for the financial year ended on 31 December 2025 (the **2025 Financial Year**);
2. Approval of the annual accounts of the Company for the 2025 Financial Year;
3. Acknowledgment of the Company's results made with respect to the 2025 Financial Year, and resolution concerning the allocation of the results;
4. Presentation of the management report issued by the manager and general partner of the Company (the **General Partner**) and the report of the independent auditor on the consolidated accounts for the 2025 Financial Year;
5. Approval of the consolidated accounts for the 2025 Financial Year;
6. Granting of discharge (*quitus*) to Mr. Georges Bock, member of the supervisory board of the Company (the **Supervisory Board**), for the exercise of his mandate during the 2025 Financial Year;
7. Granting of discharge (*quitus*) to Prof. Dr. Heinz Jörg Fuhrmann, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
8. Granting of discharge (*quitus*) to Mr. Roland Lienau, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
9. Granting of discharge (*quitus*) to Mr. Florian Schuhbauer, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
10. Granting of discharge (*quitus*) to Mr. Thomas Terschluse, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
11. Granting of discharge (*quitus*) to Mr. Markus Lesser, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
12. Granting of discharge (*quitus*) to Mr. Klaus Röhrig, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;

13. Granting of discharge (*quitus*) to the General Partner for the exercise of its mandate as manager of the Company for the 2025 Financial Year;
14. Presentation of and advisory vote on the remuneration report for the 2025 Financial Year;
15. Approval of the fixed annual remuneration of the members of the Supervisory Board for the 2026 Financial Year;
16. Renewal of the mandate of Mr. Georges Bock as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
17. Renewal of the mandate of Prof. Dr. Heinz Jörg Fuhrmann as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
18. Renewal of the mandate of Mr. Roland Lienau as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
19. Renewal of the mandate of Mr. Thomas Terschluse as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
20. Renewal of the mandate of Mr. Markus Lesser as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
21. Renewal of the mandate of Mr. Klaus Röhrig as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
22. Decision to renew BDO Audit's mandate as independent auditor (*réviseur d'entreprises agréé*) of the Company for a term expiring at the annual general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2026 to be held in 2027; and
23. Miscellaneous.

II. Agenda of the EGM

1. Acknowledgment of the report prepared by the General Partner of the Company in accordance with Article 420-26(5) of the Luxembourg law dated 10 August 1915 on commercial companies, as amended (the Law) regarding the proposed renewal of the authorised capital of the Company and the authorisation to limit or suppress the preferential subscription rights of existing shareholders regarding shares issued thereunder;
2. Decision to renew the authorised capital of the Company, for a new period of five years starting on the date of the EGM, and to grant the authorisation to the General Partner to issue up to one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) ordinary shares;
3. Decision to authorise the General Partner to limit or suppress the preferential subscription rights of existing shareholders in the event of any increase in the issued share capital up to and including the authorised capital;
4. Decision to amend article 5.4 of the Company's articles of association so as to read as follows:
"5.4 *The authorised capital, excluding the issued share capital, is set at two million three hundred forty-one thousand one hundred nine euro and twenty-four cents (EUR 2,341,109.24), consisting of one hundred fifty-four million six hundred thirty-six thousand three*

hundred fourteen (154,636,314) Ordinary Shares without nominal value. During a period of five (5) years from the extraordinary general meeting of shareholders of the Company held on 17 June 2026, the Manager is hereby authorised to issue Ordinary Shares to such persons and on such terms as they shall see fit and specifically to proceed to such issue without reserving a preferential right to subscribe to the shares issued for the existing shareholders, and it being understood, that any issuance of such instruments will reduce the available authorised capital accordingly. The authorised capital of the Company may be increased or reduced by a resolution of the general meeting of shareholders adopted in the manner required for an amendment of these articles of association. The above authorisations may be renewed through a resolution of the general meeting of the shareholders adopted in the manner required for an amendment of these articles of association and subject to the provisions of the Law, each time for a period not exceeding five (5) years.”

5. Decision to include an additional article 5.5 and an additional article 5.6 in the Company’s articles of association which shall read as follows:

“5.5 The Manager is authorised to determine the conditions of any capital increase within the limits of the authorised capital including through contributions in cash or in kind, by the incorporation of reserves, issue premiums or retained earnings, with or without the issue of new Ordinary Shares, or following the issue and the exercise of subordinated or non-subordinated bonds, convertible into or repayable by or exchangeable for Ordinary Shares (whether provided in the terms at issue or subsequently provided), or following the issue of bonds with warrants or other rights to subscribe for Ordinary Shares attached, or through the issue of stand-alone warrants or any other instrument carrying an entitlement to, or the right to subscribe for, Ordinary Shares.

5.6 The Manager is authorised to set the subscription price, with or without issue premium, the date from which the Ordinary Shares or other financial instruments will carry beneficial rights and, if applicable, the duration, amortisation, other rights (including early repayment), interest rates, conversion rates and exchange rates of the aforesaid financial instruments as well as all the other conditions and terms of such financial instruments including as to their subscription, issue and payment, for which the Manager may make use of Article 420-23 paragraph 3 of the Law.”

The present participation declaration must be returned to **CAPTRACE GmbH**, with registered office at Appelallee 27, 65203 Wiesbaden, Germany, attn: Ms Corinna Fischer (fax: +49 8943780823 and e-mail: agm@captrace.com) by mail, fax or by e-mail no later than on 2 June 2026 at 11:59 CEST.

Signed in _____, on _____.

Name:

Represented by:

Title:

Schedule 2

PROXY

FOR THE ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

The undersigned, _____, having his/her/its address at _____ and, if applicable, with commercial register number _____ (the **Shareholder**),

in his/her/its capacity as shareholder of the Company (as defined below), holding _____ ordinary shares, as shown on the attached copy/-ies of the certificate(s) evidencing the shareholding on the Record Date,

hereby gives special power of attorney, with power of substitution, to (i) Mr Jan Klopp, with professional residence at 19, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg, and/or (ii) **CAPTRACE GmbH**, with registered office at Äppelallee 27, 65203 Wiesbaden, Germany, and represented by Ms Corinna Fischer, each acting individually (each of them being referred individually to as an **Attorney**),

in order for the Attorney, acting in the name and on behalf of the Shareholder, to represent the Shareholder at the annual general meeting and at the extraordinary general meeting of the shareholders of **H2APEX Group SCA**, a partnership limited by shares (*société en commandite par actions*) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 19, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg, and registered with the Luxembourg Trade and Companies Register (*Registre de Commerce et des Sociétés de Luxembourg*) under number B148525 (the **Company**), which will take place in Luxembourg, Grand Duchy of Luxembourg, on 17 June 2026 (the **Meetings**), in order to deliberate and vote on the following agenda:

I. Agenda of the AGM

1. Presentation of the report of the independent auditor on the annual accounts of the Company for the financial year ended on 31 December 2025 (the **2025 Financial Year**);
2. Approval of the annual accounts of the Company for the 2025 Financial Year;
3. Acknowledgment of the Company's results made with respect to the 2025 Financial Year, and resolution concerning the allocation of the results;
4. Presentation of the management report issued by the manager and general partner of the Company (the **General Partner**) and the report of the independent auditor on the consolidated accounts for the 2025 Financial Year;
5. Approval of the consolidated accounts for the 2025 Financial Year;
6. Granting of discharge (*quitus*) to Mr. Georges Bock, member of the supervisory board of the Company (the **Supervisory Board**), for the exercise of his mandate during the 2025 Financial Year;
7. Granting of discharge (*quitus*) to Prof. Dr. Heinz Jörg Fuhrmann, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
8. Granting of discharge (*quitus*) to Mr. Roland Lienau, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
9. Granting of discharge (*quitus*) to Mr. Florian Schuhbauer, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
10. Granting of discharge (*quitus*) to Mr. Thomas Terschluse, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;

11. Granting of discharge (*quitus*) to Mr. Markus Lesser, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
12. Granting of discharge (*quitus*) to Mr. Klaus Röhrig, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
13. Granting of discharge (*quitus*) to the General Partner for the exercise of its mandate as manager of the Company for the 2025 Financial Year;
14. Presentation of and advisory vote on the remuneration report for the 2025 Financial Year;
15. Approval of the fixed annual remuneration of the members of the Supervisory Board for the 2026 Financial Year;
16. Renewal of the mandate of Mr. Georges Bock as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
17. Renewal of the mandate of Prof. Dr. Heinz Jörg Fuhrmann as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
18. Renewal of the mandate of Mr. Roland Lienau as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
19. Renewal of the mandate of Mr. Thomas Terschluse as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
20. Renewal of the mandate of Mr. Markus Lesser as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
21. Renewal of the mandate of Mr. Klaus Röhrig as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
22. Decision to renew BDO Audit's mandate as independent auditor (*réviseur d'entreprises agréé*) of the Company for a term expiring at the annual general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2026 to be held in 2027; and
23. Miscellaneous.

II. Agenda of the EGM

1. Acknowledgment of the report prepared by the General Partner of the Company in accordance with Article 420-26(5) of the Luxembourg law dated 10 August 1915 on commercial companies, as amended (the Law) regarding the proposed renewal of the authorised capital of the Company and the authorisation to limit or suppress the preferential subscription rights of existing shareholders regarding shares issued thereunder;
2. Decision to renew the authorised capital of the Company, for a new period of five years starting on the date of the EGM, and to grant the authorisation to the General Partner to issue up to one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) ordinary shares;
3. Decision to authorise the General Partner to limit or suppress the preferential subscription rights of existing shareholders in the event of any increase in the issued share capital up to and including the authorised capital;

4. Decision to amend article 5.4 of the Company's articles of association so as to read as follows:
- “5.4 The authorised capital, excluding the issued share capital, is set at two million three hundred forty-one thousand one hundred nine euro and twenty-four cents (EUR 2,341,109.24), consisting of one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) Ordinary Shares without nominal value. During a period of five (5) years from the extraordinary general meeting of shareholders of the Company held on 17 June 2026, the Manager is hereby authorised to issue Ordinary Shares to such persons and on such terms as they shall see fit and specifically to proceed to such issue without reserving a preferential right to subscribe to the shares issued for the existing shareholders, and it being understood, that any issuance of such instruments will reduce the available authorised capital accordingly. The authorised capital of the Company may be increased or reduced by a resolution of the general meeting of shareholders adopted in the manner required for an amendment of these articles of association. The above authorisations may be renewed through a resolution of the general meeting of the shareholders adopted in the manner required for an amendment of these articles of association and subject to the provisions of the Law, each time for a period not exceeding five (5) years.”*
5. Decision to include an additional article 5.5 and an additional article 5.6 in the Company's articles of association which shall read as follows:
- “5.5 The Manager is authorised to determine the conditions of any capital increase within the limits of the authorised capital including through contributions in cash or in kind, by the incorporation of reserves, issue premiums or retained earnings, with or without the issue of new Ordinary Shares, or following the issue and the exercise of subordinated or non-subordinated bonds, convertible into or repayable by or exchangeable for Ordinary Shares (whether provided in the terms at issue or subsequently provided), or following the issue of bonds with warrants or other rights to subscribe for Ordinary Shares attached, or through the issue of stand-alone warrants or any other instrument carrying an entitlement to, or the right to subscribe for, Ordinary Shares.*
- 5.6 The Manager is authorised to set the subscription price, with or without issue premium, the date from which the Ordinary Shares or other financial instruments will carry beneficial rights and, if applicable, the duration, amortisation, other rights (including early repayment), interest rates, conversion rates and exchange rates of the aforesaid financial instruments as well as all the other conditions and terms of such financial instruments including as to their subscription, issue and payment, for which the Manager may make use of Article 420-23 paragraph 3 of the Law.”*

The Attorney is instructed to vote in the following manner¹:

PROPOSED RESOLUTIONS AGM

1. The Annual General Meeting acknowledges the presentation by the Chairman of the report of the independent auditor on the annual accounts of the Company for the 2025 Financial Year.	No vote required						
2. The Annual General Meeting resolves to approve the annual accounts of the Company for the 2025 Financial Year.	<table style="width: 100%; border: none;"> <tr> <td style="text-align: center;">YES</td> <td style="text-align: center;">NO</td> <td style="text-align: center;">ABSTAIN</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO	ABSTAIN					
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					

¹ Please mark your decision by a cross in the corresponding space reserved to that effect below.

<p>3. The Annual General Meeting acknowledges the Company's result and further resolves to allocate the loss of hundred eighty-two million eight hundred five thousand four hundred and fifteen euros and eighty-two cents (EUR 182,805,415.82) for the 2025 Financial Year, as follows:</p> <table border="1" data-bbox="212 376 1109 633"> <tr> <td data-bbox="212 376 751 450">Result brought forward from previous financial years</td> <td data-bbox="751 376 858 450">EUR</td> <td data-bbox="858 376 1109 450">10,695,528.45</td> </tr> <tr> <td data-bbox="212 450 751 488">Result of the 2025 Financial Year</td> <td data-bbox="751 450 858 488">EUR</td> <td data-bbox="858 450 1109 488">(182,805,415.82)</td> </tr> <tr> <td data-bbox="212 488 751 562">Result to be allocated to the legal reserve</td> <td data-bbox="751 488 858 562">EUR</td> <td data-bbox="858 488 1109 562">0.00</td> </tr> <tr> <td data-bbox="212 562 751 633">Result to be carried forward to the next financial year</td> <td data-bbox="751 562 858 633">EUR</td> <td data-bbox="858 562 1109 633">(172,109,887.37)</td> </tr> </table>	Result brought forward from previous financial years	EUR	10,695,528.45	Result of the 2025 Financial Year	EUR	(182,805,415.82)	Result to be allocated to the legal reserve	EUR	0.00	Result to be carried forward to the next financial year	EUR	(172,109,887.37)	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
Result brought forward from previous financial years	EUR	10,695,528.45											
Result of the 2025 Financial Year	EUR	(182,805,415.82)											
Result to be allocated to the legal reserve	EUR	0.00											
Result to be carried forward to the next financial year	EUR	(172,109,887.37)											
<p>4. The Annual General Meeting acknowledges the presentation by the Chairman of the management report issued by the General Partner and the report of the independent auditor on the consolidated accounts for the 2025 Financial Year.</p>	<p>No vote required</p>												
<p>5. The Annual General Meeting resolves to approve the consolidated accounts for the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>6. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Georges Bock, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>7. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Prof. Dr. Heinz Jörg Fuhrmann, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>8. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Roland Lienau, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>9. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Florian Schuhbauer, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>10. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Thomas Terschluse, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												

11. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Markus Lesser, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
12. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Klaus Röhrig, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
13. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to the General Partner for the exercise of its mandate as manager of the Company during the 2025 Financial Year.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
14. The Annual General Meeting resolves to acknowledge and to cast its advisory vote on the remuneration report for the financial year ended 31 December 2025.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
<p>15. The Annual General Meeting resolves to approve the fixed annual remuneration of the members of the Supervisory Board for the financial year to end on 31 December 2026 as follows:</p> <table border="1" data-bbox="199 1041 1109 1288"> <tr> <td>Chairman of the Supervisory Board</td> <td>EUR 120,000</td> </tr> <tr> <td>Member of the Supervisory Board</td> <td>EUR 50,000</td> </tr> <tr> <td>Chairman of the Audit Committee (in addition to the Supervisory Board membership remuneration)</td> <td>EUR 20,000</td> </tr> </table>	Chairman of the Supervisory Board	EUR 120,000	Member of the Supervisory Board	EUR 50,000	Chairman of the Audit Committee (in addition to the Supervisory Board membership remuneration)	EUR 20,000	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chairman of the Supervisory Board	EUR 120,000												
Member of the Supervisory Board	EUR 50,000												
Chairman of the Audit Committee (in addition to the Supervisory Board membership remuneration)	EUR 20,000												
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
16. The Annual General Meeting resolves to renew the mandate of Mr. Georges Bock as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
17. The Annual General Meeting resolves to renew the mandate of Prof. Dr. Heinz Jörg Fuhrmann as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
18. The Annual General Meeting resolves to renew the mandate of Mr. Roland Lienau as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

<p>19. The Annual General Meeting resolves to renew the mandate of Mr. Thomas Terschluse as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>20. The Annual General Meeting resolves to renew the mandate of Mr. Markus Lesser as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>21. The Annual General Meeting resolves to renew the mandate of Mr. Klaus Röhrig as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>22. The Annual General Meeting resolves to renew BDO Audit's mandate as independent auditor (<i>réviseur d'entreprises agréé</i>) of the Company for a term expiring at the annual general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2026 to be held in 2027.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>

PROPOSED RESOLUTIONS EGM

<p>1. The Extraordinary General Meeting acknowledges the report prepared by the General Partner of the Company in accordance with Article 420-26(5) of the Luxembourg law dated 10 August 1915 on commercial companies, as amended (the Law) regarding the proposed renewal of the authorised capital of the Company and the authorisation to limit or suppress the preferential subscription rights of existing shareholders regarding shares issued thereunder.</p>	<p>No vote required</p>
<p>2. The Extraordinary General Meeting resolves to renew the authorised capital of the Company, for a new period of five years starting on the date of the Extraordinary General Meeting, and to grant the authorisation to the General Partner to issue up to one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) ordinary shares.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>3. The Extraordinary General Meeting resolves to authorise the General Partner to limit or suppress the preferential subscription rights of existing shareholders in the event of any increase in the issued share capital up to and including the authorised capital.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>

4. The Extraordinary General Meeting resolves to amend article 5.4 of the Company's articles of association which shall henceforth read as set forth in the agenda.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO	ABSTAIN					
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					
5. The Extraordinary General Meeting resolves to include an additional article 5.5 and an additional article 5.6 in the Company's articles of association which shall read as set forth in the agenda.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO	ABSTAIN					
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					

Any omission, unclearly expressed or contradictory choice in one or more of the various voting instruction options provided above will be considered as an instruction to abstain from voting in respect of the proposed resolution of the Meetings.

In case of a conflict of interest, the Attorney shall disclose certain specified facts which may be relevant for the Shareholder in assessing any risk that the Attorney might pursue any interest other than the interest of the Shareholder.

This proxy can be revoked by delivering a properly executed later dated proxy form or correspondence voting form or a declaration to revoke such proxy to **CAPTRACE GmbH**, with registered office at Äppelallee 27, 65203 Wiesbaden, Germany, attn: Ms Corinna Fischer (fax: +49 8943780823 and e-mail: agm@captrace.com), in a timely fashion and in any case no later than on 14 June 2026 at 11:59 p.m. CEST.

The present proxy form must be returned to CAPTRACE GmbH by mail, fax or by e-mail no later than on 14 June 2026 at 11:59 CEST.

This proxy is governed by, and shall be construed in accordance with, the laws of the Grand Duchy of Luxembourg. The competent courts of the district of the city of Luxembourg shall have exclusive jurisdiction to hear any dispute or controversy arising out of or in connection with this proxy form.

Signed in _____, on _____.

Name:

Represented by:

Title:

Schedule 3

CORRESPONDENCE VOTING FORM

FOR THE ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS

The undersigned, _____, having his/her/its registered office/address at _____ and, if applicable, with commercial register number _____ (the **Shareholder**),

in his/her/its capacity as shareholder of the Company (as defined below), holding _____ ordinary shares, as shown on the attached copy/-ies of the certificate(s) evidencing the shareholding on the Record Date of **H2APEX Group SCA**, a partnership limited by shares (*société en commandite par actions*) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 19, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg, and registered with the Luxembourg Trade and Companies Register (*Registre du Commerce et des Sociétés de Luxembourg*) under number B148525 (the **Company**),

hereby declares that he/she/it is not attending in person the annual general meeting and the extraordinary general meeting of shareholders of the Company to be held on 17 June 2026 at 11:00 a.m. CEST with the following agenda (the **Meetings**):

I. Agenda of the AGM

- (1) Presentation of the report of the independent auditor on the annual accounts of the Company for the financial year ended on 31 December 2025 (the **2025 Financial Year**);
- (2) Approval of the annual accounts of the Company for the 2025 Financial Year;
- (3) Acknowledgment of the Company's results made with respect to the 2025 Financial Year, and resolution concerning the allocation of the results;
- (4) Presentation of the management report issued by the manager and general partner of the Company (the **General Partner**) and the report of the independent auditor on the consolidated accounts for the 2025 Financial Year;
- (5) Approval of the consolidated accounts for the 2025 Financial Year;
- (6) Granting of discharge (*quitus*) to Mr. Georges Bock, member of the supervisory board of the Company (the **Supervisory Board**), for the exercise of his mandate during the 2025 Financial Year;
- (7) Granting of discharge (*quitus*) to Prof. Dr. Heinz Jörg Fuhrmann, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
- (8) Granting of discharge (*quitus*) to Mr. Roland Lienau, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
- (9) Granting of discharge (*quitus*) to Mr. Florian Schuhbauer, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
- (10) Granting of discharge (*quitus*) to Mr. Thomas Terschlose, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
- (11) Granting of discharge (*quitus*) to Mr. Markus Lesser, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
- (12) Granting of discharge (*quitus*) to Mr. Klaus Röhrig, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year;
- (13) Granting of discharge (*quitus*) to the General Partner for the exercise of its mandate as manager of the Company for the 2025 Financial Year;

- (14) Presentation of and advisory vote on the remuneration report for the 2025 Financial Year;
- (15) Approval of the fixed annual remuneration of the members of the Supervisory Board for the 2026 Financial Year;
- (16) Renewal of the mandate of Mr. Georges Bock as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
- (17) Renewal of the mandate of Prof. Dr. Heinz Jörg Fuhrmann as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
- (18) Renewal of the mandate of Mr. Roland Lienau as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
- (19) Renewal of the mandate of Mr. Thomas Terschluse as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
- (20) Renewal of the mandate of Mr. Markus Lesser as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
- (21) Renewal of the mandate of Mr. Klaus Röhrig as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029;
- (22) Decision to renew BDO Audit's mandate as independent auditor (*réviseur d'entreprises agréé*) of the Company for a term expiring at the annual general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2026 to be held in 2027; and
- (23) Miscellaneous.

II. Agenda of the EGM

- (1) Acknowledgment of the report prepared by the General Partner of the Company in accordance with Article 420-26(5) of the Luxembourg law dated 10 August 1915 on commercial companies, as amended (the Law) regarding the proposed renewal of the authorised capital of the Company and the authorisation to limit or suppress the preferential subscription rights of existing shareholders regarding shares issued thereunder;
- (2) Decision to renew the authorised capital of the Company, for a new period of five years starting on the date of the EGM, and to grant the authorisation to the General Partner to issue up to one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) ordinary shares;
- (3) Decision to authorise the General Partner to limit or suppress the preferential subscription rights of existing shareholders in the event of any increase in the issued share capital up to and including the authorised capital;
- (4) Decision to amend article 5.4 of the Company's articles of association so as to read as follows:

“5.4 The authorised capital, excluding the issued share capital, is set at two million three hundred forty-one thousand one hundred nine euro and twenty-four cents (EUR 2,341,109.24), consisting of one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) Ordinary Shares without nominal value. During a period of five (5) years from the extraordinary general meeting of shareholders of the Company held on 17 June 2026, the Manager is hereby authorised to issue Ordinary Shares to such persons

and on such terms as they shall see fit and specifically to proceed to such issue without reserving a preferential right to subscribe to the shares issued for the existing shareholders, and it being understood, that any issuance of such instruments will reduce the available authorised capital accordingly. The authorised capital of the Company may be increased or reduced by a resolution of the general meeting of shareholders adopted in the manner required for an amendment of these articles of association. The above authorisations may be renewed through a resolution of the general meeting of the shareholders adopted in the manner required for an amendment of these articles of association and subject to the provisions of the Law, each time for a period not exceeding five (5) years.”

- (5) Decision to include an additional article 5.5 and an additional article 5.6 in the Company’s articles of association which shall read as follows:

“5.5 The Manager is authorised to determine the conditions of any capital increase within the limits of the authorised capital including through contributions in cash or in kind, by the incorporation of reserves, issue premiums or retained earnings, with or without the issue of new Ordinary Shares, or following the issue and the exercise of subordinated or non-subordinated bonds, convertible into or repayable by or exchangeable for Ordinary Shares (whether provided in the terms at issue or subsequently provided), or following the issue of bonds with warrants or other rights to subscribe for Ordinary Shares attached, or through the issue of stand-alone warrants or any other instrument carrying an entitlement to, or the right to subscribe for, Ordinary Shares.

5.6 The Manager is authorised to set the subscription price, with or without issue premium, the date from which the Ordinary Shares or other financial instruments will carry beneficial rights and, if applicable, the duration, amortisation, other rights (including early repayment), interest rates, conversion rates and exchange rates of the aforesaid financial instruments as well as all the other conditions and terms of such financial instruments including as to their subscription, issue and payment, for which the Manager may make use of Article 420-23 paragraph 3 of the Law.”

The Shareholder hereby votes as follows on the proposed resolutions of the Meetings²:

PROPOSED RESOLUTIONS AGM

1. The Annual General Meeting acknowledges the presentation by the chairman of the report of the independent auditor on the annual accounts of the Company for the 2025 Financial Year.	No vote required						
2. The Annual General Meeting resolves to approve the annual accounts of the Company for the 2025 Financial Year.	<table style="width: 100%; border: none;"> <tr> <td style="text-align: center;">YES</td> <td style="text-align: center;">NO</td> <td style="text-align: center;">ABSTAIN</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO	ABSTAIN					
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					

² Please mark your decision by a cross in the corresponding space reserved to that effect below.

<p>3. The Annual General Meeting acknowledges the Company's result and further resolves to allocate the loss of one hundred eighty-two million eight hundred five thousand four hundred and fifteen euros and eighty-two cents (EUR 182,805,415.82) for the 2025 Financial Year, as follows:</p> <table border="1" data-bbox="212 376 1109 633"> <tr> <td data-bbox="212 376 751 450">Result brought forward from previous financial years</td> <td data-bbox="751 376 858 450">EUR</td> <td data-bbox="858 376 1109 450">10,695,528.45</td> </tr> <tr> <td data-bbox="212 450 751 488">Result of the 2025 Financial Year</td> <td data-bbox="751 450 858 488">EUR</td> <td data-bbox="858 450 1109 488">(182,805,415.82)</td> </tr> <tr> <td data-bbox="212 488 751 562">Result to be allocated to the legal reserve</td> <td data-bbox="751 488 858 562">EUR</td> <td data-bbox="858 488 1109 562">0.00</td> </tr> <tr> <td data-bbox="212 562 751 633">Result to be carried forward to the next financial year</td> <td data-bbox="751 562 858 633">EUR</td> <td data-bbox="858 562 1109 633">(172,109,887.37)</td> </tr> </table>	Result brought forward from previous financial years	EUR	10,695,528.45	Result of the 2025 Financial Year	EUR	(182,805,415.82)	Result to be allocated to the legal reserve	EUR	0.00	Result to be carried forward to the next financial year	EUR	(172,109,887.37)	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
Result brought forward from previous financial years	EUR	10,695,528.45											
Result of the 2025 Financial Year	EUR	(182,805,415.82)											
Result to be allocated to the legal reserve	EUR	0.00											
Result to be carried forward to the next financial year	EUR	(172,109,887.37)											
<p>4. The Annual General Meeting acknowledges the presentation by the Chairman of the management report issued by the General Partner and the report of the independent auditor on the consolidated accounts for the 2025 Financial Year.</p>	<p>No vote required</p>												
<p>5. The Annual General Meeting resolves to approve the consolidated accounts for the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>6. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Georges Bock, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>7. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Prof. Dr. Heinz Jörg Fuhrmann, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>8. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Roland Lienau, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>9. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Florian Schuhbauer, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												
<p>10. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Thomas Terschluse, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.</p>	<p>YES NO ABSTAIN</p> <p><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>												

11. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Markus Lesser, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
12. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to Mr. Klaus Röhrig, member of the Supervisory Board, for the exercise of his mandate during the 2025 Financial Year.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
13. The Annual General Meeting resolves to grant discharge (<i>quitus</i>) to the General Partner for the exercise of its mandate as manager of the Company during the 2025 Financial Year.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
14. The Annual General Meeting resolves to acknowledge and to cast its advisory vote on the remuneration report for the financial year ended 31 December 2025.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
<p>15. The Annual General Meeting resolves to approve the fixed annual remuneration of the members of the Supervisory Board for the financial year to end on 31 December 2026 as follows:</p> <table border="1" data-bbox="199 1041 1109 1288"> <tr> <td>Chairman of the Supervisory Board</td> <td>EUR 120,000</td> </tr> <tr> <td>Member of the Supervisory Board</td> <td>EUR 50,000</td> </tr> <tr> <td>Chairman of the Audit Committee (in addition to the Supervisory Board membership remuneration)</td> <td>EUR 20,000</td> </tr> </table>	Chairman of the Supervisory Board	EUR 120,000	Member of the Supervisory Board	EUR 50,000	Chairman of the Audit Committee (in addition to the Supervisory Board membership remuneration)	EUR 20,000	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chairman of the Supervisory Board	EUR 120,000												
Member of the Supervisory Board	EUR 50,000												
Chairman of the Audit Committee (in addition to the Supervisory Board membership remuneration)	EUR 20,000												
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
16. The Annual General Meeting resolves to renew the mandate of Mr. Georges Bock as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
17. The Annual General Meeting resolves to renew the mandate of Prof. Dr. Heinz Jörg Fuhrmann as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
18. The Annual General Meeting resolves to renew the mandate of Mr. Roland Lienau as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.	<table border="0"> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>						
YES	NO	ABSTAIN											
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

<p>19. The Annual General Meeting resolves to renew the mandate of Mr. Thomas Terschluse as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>20. The Annual General Meeting resolves to renew the mandate of Mr. Markus Lesser as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>21. The Annual General Meeting resolves to renew the mandate of Mr. Klaus Röhrig as member of the Supervisory Board for a term expiring at the general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2028 to be held in 2029.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>22. The Annual General Meeting resolves to renew BDO Audit's mandate as independent auditor (<i>réviseur d'entreprises agréé</i>) of the Company for a term expiring at the annual general meeting of shareholders of the Company approving the annual accounts relating to the financial year ending on 31 December 2026 to be held in 2027.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>

PROPOSED RESOLUTIONS EGM

<p>1. The Extraordinary General Meeting acknowledges the report prepared by the General Partner of the Company in accordance with Article 420-26(5) of the Luxembourg law dated 10 August 1915 on commercial companies, as amended (the Law) regarding the proposed renewal of the authorised capital of the Company and the authorisation to limit or suppress the preferential subscription rights of existing shareholders regarding shares issued thereunder.</p>	<p>No vote required</p>
<p>2. The Extraordinary General Meeting resolves to renew the authorised capital of the Company, for a new period of five years starting on the date of the Extraordinary General Meeting, and to grant the authorisation to the General Partner to issue up to one hundred fifty-four million six hundred thirty-six thousand three hundred fourteen (154,636,314) ordinary shares.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>
<p>3. The Extraordinary General Meeting resolves to authorise the General Partner to limit or suppress the preferential subscription rights of existing shareholders in the event of any increase in the issued share capital up to and including the authorised capital.</p>	<p>YES NO ABSTAIN <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>

4. The Extraordinary General Meeting resolves to amend article 5.4 of the Company's articles of association which shall henceforth read as set forth in the agenda.	<table> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO	ABSTAIN					
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					
5. The Extraordinary General Meeting resolves to include an additional article 5.5 and an additional article 5.6 in the Company's articles of association which shall read as set forth in the agenda.	<table> <tr> <td>YES</td> <td>NO</td> <td>ABSTAIN</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	YES	NO	ABSTAIN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO	ABSTAIN					
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					

Any omission, unclearly expressed or contradictory choice in one or more of the various voting options provided above are going to be considered as an abstention from voting for the relevant resolution of the Meetings.

Shareholders having submitted a voting form but who wish to revoke such voting form may do so by providing a properly executed later dated proxy form or correspondence voting form or cancelling the correspondence voting form in writing to **CAPTRACE GmbH**, with registered office at Äppelallee 27, 65203 Wiesbaden, Germany, attn: Ms Corinna Fischer (fax: +49 8943780823 and e-mail: agm@captrace.com), in a timely fashion and in any case no later than on 14 June 2026 at 11:59 p.m. CEST.

The present correspondence voting form must be returned to CAPTRACE GmbH by mail, fax or by e-mail no later than 14 June 2026 at 11:59 CEST.

This correspondence voting is governed by, and shall be construed in accordance with, the laws of the Grand Duchy of Luxembourg. The competent courts of the district of the city of Luxembourg shall have exclusive jurisdiction to hear any dispute or controversy arising out of or in connection with this correspondence voting.

Signed in _____, on _____.

Name:

Represented by:

Title: